title: Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer.
abstract: OBJECTIVE
  The evaluation of toxicity after high-dose-rate interstitial brachytherapy (HDR-ISBT) as monotherapy for localized prostate cancer.
  
  
  METHODS
  We analyzed early and late toxicities in 100 patients treated by HDR-ISBT as monotherapy at the National Hospital Organization Osaka National Hospital using both Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) and Radiation Therapy Oncology Group (RTOG) score. The median follow-up was 72 (range=12-109) months.
  
  
  RESULTS
  Late-gastrointestinal (GI) toxicities were 4% grade 1 and 2% grade 2 in CTCAE v3.0 and 5% grade 1 in RTOG score. Late genitourinary (GU) toxicities grade 1: grade 2: grade 3 were 29%: 5%: 2% in RTOG and 47%: 10%: 2% in CTCAE v3.0. CTCAE v3.0 GU score identified more grade 1-2 adverse reactions than the RTOG score (p=0.01). Early RTOG GI toxicity-positive patients showed 13% of late RTOG GI toxicity, whereas early RTOG GI negative patients showed 0% of RTOG (p=0.0172) and CTCAE v3.0 late-GI toxicity (p=0.007).
  
  
  CONCLUSIONS
  CTCAE v3.0 GU score identified more grade 1-2 adverse reactions than the RTOG score. Early RTOG GI toxicity is well-correlated to late GI toxicity and absence of RTOG acute GI toxicity is a safe surrogate for late GI toxicity after HDR-ISBT as monotherapy for prostate cancer.
authors.affiliation: Department of Radiology, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto, Kyoto 602-8566 Japan. hideya10@hotmail.com.
authors.forename: Ken
authors.initials: K
authors.lastname: Yoshida
authors.forename: Hideya
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Satoaki
authors.initials: S
authors.lastname: Nakamara
authors.forename: Koji
authors.initials: K
authors.lastname: Masui
authors.forename: Tadayuki
authors.initials: T
authors.lastname: Kotsuma
authors.forename: Hironori
authors.initials: H
authors.lastname: Akiyama
authors.forename: Eiichi
authors.initials: E
authors.lastname: Tanaka
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yoshioka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects*; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D014570:Urologic Diseases / Q000175:diagnosis / Q000209:etiology
keywords: High dose rate brachytherapy; early toxicity; interstitial brachytherapy; late toxicity; prostate cancer; radiation therapy